Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses?

@article{Fung2017IsAL,
  title={Is a lower dose of cyproterone acetate as effective at testosterone suppression in transgender women as higher doses?},
  author={R. Fung and Miriam Hellstern-Layefsky and I. Lega},
  journal={International Journal of Transgenderism},
  year={2017},
  volume={18},
  pages={123 - 128}
}
  • R. Fung, Miriam Hellstern-Layefsky, I. Lega
  • Published 2017
  • Medicine
  • International Journal of Transgenderism
  • ABSTRACT Objective: The recommended dose of cyproterone acetate (CPA), an anti-androgen that is commonly used in the hormonal treatment of transgender women, is 50–100 mg daily. Our objective was to determine whether CPA at 25 mg daily would suppress total testosterone as effectively as 50 mg daily in transgender women. Methods: We conducted a retrospective cohort analysis of transgender women attending an endocrinology clinic between April 1, 2009, and June 30, 2015. We used a generalized… CONTINUE READING
    4 Citations

    Topics from this paper.

    References

    SHOWING 1-10 OF 17 REFERENCES
    Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
    • 105
    • Highly Influential
    • PDF
    A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
    • 301
    • PDF
    Venous thrombosis and changes of hemostatic variables during cross-sex hormone treatment in transsexual people.
    • 154
    • PDF
    Long-term evaluation of cross-sex hormone treatment in transsexual persons.
    • 185
    Hepatotoxicity induced by cyproterone acetate: a report of three cases.
    • 34
    Epidemiology of hormonal contraceptives-related venous thromboembolism.
    • 46
    • PDF
    [Combined oral contraceptives].
    • 25
    • PDF
    Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline.
    • 792
    • PDF